Betameth

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betameth

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical preparation (Ointment, Cream, Lotion)
Pharmacological class Glucocorticoid (Corticosteroid)
Common use Relief of inflammation and itching
Origin Synthetic

What Type of Medicine is Betameth?

Betameth is a prescription-only medicinal product containing the active substance Betamethasone Dipropionate, which is classified as a potent, synthetic glucocorticoid. This compound belongs to the larger family of corticosteroids and is widely recognized for its powerful anti-inflammatory capabilities. Betamethasone Dipropionate is categorized as a high-potency topical steroid, a strength clinically recognized for addressing conditions that have proven resistant to milder preparations. As a synthetic compound, it is manufactured to possess a superior effect profile compared to naturally occurring steroid hormones for its intended dermatological use.


Composition and Topical Administration

The product is formulated as a topical preparation, designed for direct administration to the skin, typically available as an ointment, cream, lotion, or gel. This formulation strategy ensures that the potent effects of the active ingredient are concentrated locally at the affected site. The composition features the active substance, Betamethasone Dipropionate, blended into a pharmaceutical vehicle, such as a hydrophilic cream base or an occlusive ointment base. The choice of vehicle significantly impacts the drug's penetration into the skin, ensuring that the most effective physical base can be chosen to suit the specific characteristics of a patient's skin condition.


General Function and Purpose

The general purpose of Betameth is to provide rapid, targeted relief from the primary inflammatory symptoms associated with various skin conditions. The drug functions primarily by its anti-inflammatory effect and localized immunosuppressive action, which are the defining characteristics of corticosteroids. By inhibiting the complex processes that trigger the inflammatory cascade, the medicine effectively mitigates hallmark symptoms such as severe redness, swelling, and itching within the affected area.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Betameth?

Possible Side Effects and Safety Information

Betameth (Betamethasone) is associated with officially documented adverse reactions that are categorized by both the body system affected and their reported frequency, based on regulatory documentation.

Key Adverse Reaction Categories

Side effects are generally classified as either local (affecting the skin where the medicine is applied) or systemic (resulting from the medicine being absorbed into the body).

Classification Examples of Reactions
Local Reactions Skin atrophy (thinning), striae (stretch marks), telangiectasia, burning, irritation, dryness, acneiform eruptions.
Systemic Reactions Suppression of the hypothalamic-pituitary-adrenal (HPA) axis, Cushing's syndrome, hyperglycemia, and glycosuria.

Serious and Clinically Significant Risks

Regulatory documentation highlights serious safety concerns, particularly with extensive or prolonged use. The systemic absorption of the medicine carries a risk of HPA axis suppression, which can affect the body's ability to respond to stress. In children, systemic absorption may also lead to intracranial hypertension and a greater risk of toxicity due to their body composition.

Specific risks to the eyes are also noted, including the potential development of posterior subcapsular cataracts and glaucoma if the medicine comes into contact with the eyes.

Safety Considerations and Restrictions

Authorities specify that the risk of systemic adverse effects is increased with certain exposure patterns. This includes using the medicine over large body surface areas, for extended periods, or under occlusive dressings.

Regulatory guidance emphasizes caution in pediatric patients due to their increased susceptibility to systemic toxicity. Use during pregnancy is generally limited to situations where the potential benefit is deemed to outweigh the potential risk to the fetus, based on animal study findings.

Overdose and Emergency Response

Overdose Manifestations

Systemic absorption of Betameth can produce formally documented systemic effects when applied over a large surface area, used for prolonged periods, or under occlusive dressings. These manifestations primarily affect the endocrine and metabolic systems. Documented presentations include reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, hyperglycemia, and glucosuria. Chronic overexposure may lead to signs consistent with Cushing’s syndrome.

When to Seek Immediate Medical Help

While acute overdosage from topical application is not typically expected to be life-threatening, urgent medical evaluation is necessary if manifestations of glucocorticosteroid insufficiency (steroid withdrawal) are suspected. Additionally, immediate medical attention is required if signs of a very serious allergic reaction (e.g., severe dizziness, trouble breathing, swelling) are noted.

Population-Specific Risk: Pediatric patients face a greater risk of systemic toxicity, potentially exhibiting linear growth retardation and signs of intracranial hypertension due to their higher body surface area ratio.

Official Management Procedures

  • Antidote: No specific antidote is known for systemic toxicity resulting from Betameth.
  • Action: Management involves gradual withdrawal of the drug (by reducing frequency or substitution) and administering appropriate symptomatic treatment.
  • Monitoring: HPA axis suppression is evaluated using tests such as the Urinary Free Cortisol test and ACTH stimulation test.

Therapeutic Uses of Betameth

What Betameth Treats: Main Uses and Benefits

Betameth is commonly used across conditions presenting with acute or disruptive symptom patterns, particularly for severe corticosteroid-responsive dermatoses. The medication is relevant for easing challenging symptoms associated with specific conditions, including psoriasis and pronounced cases of eczema (atopic and contact dermatitis), and is used for the relief of the inflammatory and pruritic manifestations of these conditions.

A core therapeutic benefit is its ability to help address symptom clusters that may become intense or disruptive, specifically intense pruritus (itching), alongside the core inflammatory signs of redness (erythema) and swelling (edema). Managing this cluster of symptoms is relevant, as it helps ease the overall symptom burden and supports the patient in maintaining a sense of stability during periods of heightened symptoms.

Applied in scenarios where additional management of discomfort is required, especially when conditions produce a significant symptomatic burden, Betameth may also assist in managing chronic manifestations like persistent skin thickening (lichenification) and substantial scaling. Its role is supportive:

“It is relevant when supportive symptom management is appropriate in situations where symptoms may intensify temporarily.”


Quick Fact: Symptom Management Focus

Property Description
Conditions Severe Eczema, Psoriasis, Corticosteroid-responsive Dermatoses
Symptoms Relieved Intense Itching, Redness, Swelling, Scaling
Benefit Contributes to improved comfort during acute or fluctuating manifestations

Eligibility and Restrictions for Use

Who Can and Cannot Use Betameth?

Betameth (Betamethasone Dipropionate) is authorized for use based on strict regulatory eligibility criteria, which define populations who can use the medicine, who must not use it, and under what conditions. The medicine is indicated for adults and adolescents 13 years of age and older.


Eligibility Scope

Classification Rule Summary (Official Labeling)
Contraindicated Patients with known hypersensitivity to the active ingredient, other corticosteroids, or any component of the preparation.
Not Recommended Children younger than 13 years; use for rosacea or perioral dermatitis; application in the diaper area.
Conditional Use Patients with liver failure or those requiring treatment over a large surface area or for prolonged periods.

Special Population Constraints

  • Pregnancy: Use is generally limited, only allowed if the potential benefit justifies the potential risk to the fetus, and extensive use is not recommended.
  • Lactation: Use requires caution; application must be restricted to the smallest area and for the shortest duration necessary, and must not be applied to the nipple and areola.

Regulatory documents also state that use must be avoided on areas with skin atrophy or in the presence of an uncontrolled dermatological infection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Betameth (Betamethasone Dipropionate) is a topical medicine whose potential for interaction is primarily documented through the risk of systemic absorption and subsequent additive effects with other corticosteroid-containing products. Official regulatory documents do not typically list specific drug-drug interaction tables for this topical formulation but instead focus on the resulting risk to the Hypothalamic-Pituitary-Adrenal (HPA) axis.

Documented Interaction Patterns

Category Officially Documented Information
Interacting Product Class Corticosteroid-containing products (Topical or Systemic)
Mechanism Systemic absorption potentially leading to Additive Glucocorticoid Exposure and HPA axis suppression.
Timing Requirements None explicitly documented for time separation with other medicinal products.

Co-administration with other corticosteroid products may result in an additive increase in the total systemic glucocorticoid exposure. This pharmacodynamic effect is the primary documented interaction-related restriction, as it can increase the risk of systemic effects like HPA axis suppression.

Population-Specific Interaction Notes

The risk of systemic interaction is noted to be heightened in specific patient populations due to factors influencing drug disposition:

  • Pediatric Patients are at a greater risk of systemic toxicity and HPA axis suppression.
  • Individuals with liver failure may face increased risk of systemic interaction due to altered drug clearance.

These considerations govern the management of this medicine, focusing on constraints related to systemic exposure.

Mechanism of Action

Betameth functions as a synthetic glucocorticoid receptor (GR) agonist. The lipophilic molecule diffuses across the cell membrane and binds to the cytoplasmic GR, leading to dissociation of the receptor-heat shock protein complex.

This activated Betameth-GR complex then translocates into the cell nucleus. In the nucleus, the complex modulates gene transcription primarily through two mechanisms: transactivation and transrepression. Transactivation involves binding to glucocorticoid response elements (GREs) on the DNA, which upregulates the transcription of anti-inflammatory genes, such as those encoding annexin A1 (lipocortin-1). Annexin A1 inhibits the enzyme phospholipase A2, thereby blocking the synthesis of eicosanoids, including prostaglandins and leukotrienes.

Conversely, transrepression occurs via protein-protein interactions with pro-inflammatory transcription factors, notably nuclear factor-kappa B (NF-kappaB). This interaction inhibits NF-kappaB's ability to drive the transcription of pro-inflammatory genes, resulting in a system-level suppression of various cytokines, chemokines, and adhesion molecules. The overall systemic physiological consequence involves broad vasoconstriction and a reduction in the migration and activity of immune cells, including T-lymphocytes and macrophages, leading to global immune-modulation.

Dosage and Administration Information

How to Use Betameth: Official Administration Guidelines

Betameth (Betamethasone Dipropionate) is authorized strictly for topical use and is not approved for administration by oral, ophthalmic, or internal routes. It is available in various 0.05% formulations, including cream, ointment, lotion, and spray, which dictate the specific rules for use.


Dosing, Frequency, and Volume Constraints

The standard application involves applying a thin film of the preparation only to the affected skin areas. Application frequency is typically limited to once daily; however, some labels for augmented formulations or the spray may prescribe a twice daily regimen. To manage systemic exposure, a clear volume constraint is established in regulatory labeling, specifying that the total amount used should not exceed 50 grams per week.


Duration Limits and Procedural Requirements

Therapy is intended to be short-term and must be discontinued promptly when symptom control is achieved. Specific maximum duration limits are mandated for certain dosage forms, such as no more than two consecutive weeks for the ointment, or up to four weeks for the spray. Proper administration requires that the treated area not be covered by occlusive dressings (e.g., bandages or wraps) unless a healthcare professional specifically directs this action. The spray formulation also requires the container to be shaken well before each use, and contact with the eyes or mucous membranes must be avoided.


Age-Group Usage Rules

Official usage guidelines define the authorized patient population. Cream, ointment, and lotion forms are generally indicated for individuals 13 years of age and older. The 0.05% spray formulation often restricts use to adult patients, 18 years of age or older.

Recent Clinical Evidence

Research evidence / Overview of studies for Betameth

The research on Betameth, which contains Betamethasone Dipropionate, primarily consists of studies designed to monitor and measure changes in specific skin conditions. This overview describes the research that has been conducted, the types of outcomes that were measured, and the limitations or gaps that exist in the evidence base, according to regulatory and scientific literature.


Evidence for use in Psoriasis (Plaque Psoriasis)

Research has explored the compound in studies involving patients who have plaque psoriasis, a condition characterized by thick, scaly patches. The primary evidence base consists of multiple short-term Randomized Controlled Trials (RCTs), typically spanning about four weeks. These studies were structured to monitor measurements of disease activity by using standardized rating systems, such as the Psoriasis Area and Severity Index (PASI) and the Investigator's Global Assessment (IGA). Research examined measurements of individual symptoms, like plaque thickness and scaling, during the study period.

Studies conducted during periods of increased symptom activity reported measurements of change in these established severity scores when comparing the compound to a non-active vehicle (placebo). Findings describe patterns observed in the studies related to inflammatory or irritative states. Furthermore, pooled analyses of trial data documented patterns in the assessment of individual signs over the short treatment period.

Evidence for use in Eczema (Atopic and Contact Dermatitis)

For conditions involving periods of heightened symptoms, such as Eczema, research primarily used short-term Randomized Controlled Trials (RCTs). These studies were relevant in trials assessing short-term or episodic symptom patterns and were designed to evaluate the compound against a non-active vehicle or other topical treatments. The study outcomes examined changes in severity scores, including the Eczema Area and Severity Index (EASI) and the IGA. Researchers also measured patient-reported outcomes describing perceived discomfort, exploring the severity of symptoms like pruritus (itching) and erythema (redness).

Studies monitored measurements of change in the EASI score after the treatment period when comparing the compound to a vehicle. Some studies described patterns in the assessed status of symptoms (e.g., itching and redness) based on clinician observation over the short treatment course.


What is Still Uncertain About the Research for Betameth

While research provides context about short-term measurements, there are still areas where the evidence is limited or uncertain. Long-term effects are not fully established for continuous use beyond short, defined treatment courses. Research also describes patterns observed in a limited set of studies involving adolescents (12 years and older), but there is limited research available on the use of this compound in children younger than 12 years old. The research describes group patterns, and findings do not determine whether an individual will respond similarly.

Key Studies & References

  1. Label: BETAMETHASONE DIPROPIONATE cream, augmented - DailyMed - NIH
  2. Betamethasone Topical: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Betameth (FAQ)


Q: Are the side effects of Betameth common or rare?

Official documents classify reported side effects into categories like Local (at the site of application) and Systemic (absorbed into the body). Local reactions, such as burning, stinging, or itching, are often reported as more common outcomes. Systemic effects, like those concerning the body’s hormone system (HPA axis suppression), are generally considered less frequent and are often linked to factors such as prolonged or extensive use.


Q: What should I do if I miss a dose of Betameth?

Regulatory information provides guidance for missed doses. If you remember soon after the scheduled time, you may apply the medicine. However, if it is almost time for the next application, it is advised to skip the missed dose and continue with your regular schedule. Official guidelines advise that extra medicine is generally not recommended to try and make up for a missed application.


Q: Does Betameth interact with common pain relievers like ibuprofen?

Official regulatory documents for this topical medicine highlight the primary potential interaction with other corticosteroid-containing products (topical or systemic). This is due to the risk of additive glucocorticoid exposure, which can affect the body’s hormone system. Specific drug-drug interaction tables for non-corticosteroid pain relievers are not typically included in the official topical medicine labeling.


Q: Does Betameth affect blood sugar levels?

Systemic absorption of the medicine, which is more likely with extensive or prolonged use, is associated with potential systemic side effects. Official safety documents recognize that this absorption carries the potential to cause hyperglycemia (high blood sugar) and glycosuria (sugar in the urine).


Q: Can I use Betameth if I have glaucoma or cataracts?

Regulatory documents advise caution regarding use of the medicine when a patient has pre-existing eye conditions such as glaucoma or cataracts. The medicine carries a warning that it may potentially worsen these conditions if it comes into contact with the eyes. Patients should take care to avoid eye contact.


Q: Why is Betameth regulated as a prescription-only medicine?

The medicine is classified as a potent topical corticosteroid. This classification, along with the recognized potential for significant systemic effects like HPA axis suppression with improper use, requires that patients be under medical supervision. This necessity for monitoring dictates its regulation as a prescription-only medicine.


Q: Can older adults (seniors) use Betameth safely?

Regulatory information includes Geriatric Use in the patient information, which indicates it is authorized for use in the older adult population. No general contraindications based solely on advanced age are specified, but its use is subject to the same systemic risk factors (e.g., prolonged use) as in other adults.


Q: Are there different strengths or concentrations of Betameth?

The active ingredient is primarily available in different topical formulations (like cream, ointment, or spray) at the 0.05% concentration. The potency of this single concentration is further differentiated by the vehicle used to formulate it, creating both non-augmented and augmented options, which represent different strengths of action.


Q: What if I'm taking Betameth and I need to have surgery?

The risk of systemic absorption and HPA axis suppression is a documented concern, as this affects the body’s natural ability to respond to stress. Regulatory guidance notes that situations of stress, such as major surgery, may necessitate an evaluation for supplemental systemic corticosteroids if HPA axis suppression is documented.


Q: What happens if I stop taking Betameth suddenly?

Therapy is intended to be discontinued promptly when symptom control is achieved. However, if HPA axis suppression occurs, regulatory documentation notes that signs and symptoms of steroid withdrawal may infrequently occur, sometimes requiring management with supplemental systemic corticosteroids.


Q: How long does it typically take to see a difference after starting Betameth?

Official administration guidelines suggest that if a patient does not observe any improvement in symptoms within a 2-week period, an assessment of the diagnosis and treatment plan may be needed. This timeframe is mentioned as a point for clinical review, not a promise of onset of effect.


Q: Is there a generic version of Betameth available?

Yes, the active ingredient, Betamethasone Dipropionate, is available in multiple generic formulations. These generic versions are authorized for use in the same manner as the original brand-name product.


Q: What is the difference between Betameth and a non-steroid medication for the same condition?

Betameth is classified as a potent glucocorticoid (corticosteroid), and its mechanism involves modulating gene transcription to reduce inflammation. Non-steroid medications often achieve anti-inflammatory effects through different mechanisms, such as enzyme inhibition, rather than through steroid hormone-receptor action.


Q: Are there any food or drinks that I should avoid while using Betameth?

Since this medicine is approved strictly for topical use and is not for ingestion, instructions regarding taking it with or without food are not applicable in the official documentation.


Q: How quickly does Betameth leave the body?

Once the active substance is absorbed through the skin, it enters the body's drug processing pathways. Regulatory information indicates that it is metabolized mainly in the liver and is then eliminated primarily by the kidneys, similar to other corticosteroids given systemically.


Q: If I have a mild case of the condition, is Betameth still appropriate?

The medicine is classified as a potent or super-high-potency topical corticosteroid. It is indicated for the relief of inflammatory and itchy symptoms of corticosteroid-responsive skin conditions. The determination of the appropriate potency for a specific severity level is based on a healthcare professional's assessment.


Q: Does Betameth affect my ability to drive or operate machinery?

Official prescribing information typically does not contain a warning regarding the medicine's influence on the ability to drive or operate machinery. This is consistent with the low level of systemic absorption usually anticipated from topical use.


Q: Is it possible to develop a tolerance to Betameth over time?

The medicine is intended for short-term use, and the treatment duration is limited in official guidelines. The guidance states that if no improvement is observed within 2 weeks, a reassessment of the diagnosis may be necessary, suggesting that therapy failure is a factor monitored by prescribers.


Q: Does taking Betameth with or without food change anything?

As the medicine is approved strictly for topical use and is not intended for swallowing, instructions regarding taking it with or without food are not applicable in the official documentation.


Q: Why do some people need to be monitored closely when using Betameth?

Patients may be monitored closely for signs of HPA axis suppression (a systemic effect), which affects the adrenal glands and the body's response to stress. The official labeling specifies that certain tests, like the ACTH stimulation test, may be helpful to evaluate this potential effect.


Q: What is the difference in purpose between Betameth and an antibiotic?

Betameth is classified as a potent glucocorticoid and its purpose is to reduce inflammation and itching. In contrast, the purpose of an antibiotic medicine is to inhibit the growth of or kill bacteria that cause infection.


Q: Does Betameth interfere with any common blood tests?

Systemic absorption can potentially lead to changes in the endocrine system's function, which may be detected by certain lab tests. For example, the ACTH stimulation test is explicitly mentioned in the official labeling as a tool used to evaluate potential HPA axis suppression.


Q: Is there a specific time of day best for using Betameth?

The official administration guidelines specify the required frequency of application (typically once or twice daily) but do not mandate a specific time of day (e.g., morning or evening) for use. The focus is on consistency with the prescribed frequency.

How should Betameth be stored and disposed of?

Storage and Handling Requirements

Betamethasone must be stored according to specific regulatory conditions to maintain its stability and effectiveness. The required storage environment for most formulations is Controlled Room Temperature (20 C to 25 C), with a mandatory instruction to keep the product from freezing.

Specific liquid or injectable forms must also be protected from light and may have a limited shelf-life after first opening (e.g., discard after 28 days).

Constraint Requirement
Temperature 20 C to 25 C (Do Not Freeze)
Protection Keep out of the reach and sight of children

Disposal Instructions

All unused or expired Betamethasone product must be handled as pharmaceutical waste. Official instructions state that it must not be thrown into wastewater or household trash. Disposal must occur in accordance with local requirements for unused medicine, often by returning it to a pharmacy or designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betameth found in:

A-Z Index: